Drugs / TG103
Trials 11
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Results VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF EFMEDAGLUTIDE ALFA INJECTION IN COMBINATION WITH METFORMIN IN CHINESE ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS PRESENTED IN A SHORT ORAL DISCUSSION AT THE 62ND ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD 2026) irasia.com ↗ |
| 2022-09-09 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - "TG103 INJECTION" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that “TG103 Injection”, a class 1 biological innovative drug of the Group, has been granted approval by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) in China. |
| 2022-09-09 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - "TG103 INJECTION" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE irasia.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF EFMEDAGLUTIDE ALFA INJECTION IN COMBINATION WITH METFORMIN IN CHINESE ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS PRESENTED IN A SHORT ORAL DISCUSSION AT THE 62ND ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD 2026) irasia.com ↗ |
| 2022-09-09 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - "TG103 INJECTION" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS irasia.com ↗ |
| 2022-09-09 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - "TG103 INJECTION" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE irasia.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05063253 ↗ |
| Action | Activate | “a GLP-1 receptor agonist” NCT05299697 ↗ |
| Modality | Protein / enzyme biologic | “TG103 is a novel GLP-1/Fc fusion protein” PMID 37062422 ↗ Apr 2023 |
| Route | Subcutaneous | “Following a single subcutaneous(s.c.) injections of TG103” PMID 37062422 ↗ Apr 2023 |